HESTER BIOSCIENCES LTD

During the earnings conference call held on July 30, 2026, management of Hester Biosciences Limited reported a 14% growth in standalone revenue from operations and an 88% increase in profit after tax (PAT) for Q1 FY27 compared to the same quarter last year. Gross margins improved from 69% to 78%, attributed to a favorable product mix and operational efficiencies. The Poultry Healthcare Division experienced a significant 48% growth, driven by increased institutional business and market penetration. However, consolidated revenue declined by 8%, primarily due to lower revenues from operations in Nepal and Africa. Management highlighted ongoing efforts in research and development, emphasizing the importance of innovation for long-term growth. They also discussed the challenges faced in international markets and the impact of government-led immunization programs on the Animal Healthcare Division. Overall, management expressed confidence in the company's strategic direction and long-term growth potential.

Management highlighted strong growth in key divisions and ongoing strategic initiatives.